Dynavax Technologies Revenue and Competitors
Estimated Revenue & Valuation
- Dynavax Technologies's estimated annual revenue is currently $91.8M per year.
- Dynavax Technologies's estimated revenue per employee is $217,000
- Dynavax Technologies's total funding is $1B.
Employee Data
- Dynavax Technologies has 423 Employees.
- Dynavax Technologies grew their employee count by 16% last year.
Dynavax Technologies's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Chief Human Resources Officer | Reveal Email/Phone |
3 | SVP and Chief Financial Officer | Reveal Email/Phone |
4 | VP Clinical Development | Reveal Email/Phone |
5 | SVP | Reveal Email/Phone |
6 | Head OpEx & PMO (Operational Excellence & Project Management Office) | Reveal Email/Phone |
7 | VP & Site Head (Managing Director) | Reveal Email/Phone |
8 | Safety Officer ; Senior Qualification Engineer | Reveal Email/Phone |
9 | Head, Europe and Asia Operations and Planning | Reveal Email/Phone |
10 | SVP and General Counsel | Reveal Email/Phone |
Dynavax Technologies Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Dynavax Technologies?
Dynavax is a fully-integrated biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax discovers and develops novel vaccines and immuno-oncology therapeutics. The Company?s first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax's lead immunotherapy product, SD-101, is an investigational cancer immunotherapeutic currently being evaluated in Phase 1/2 studies and its second cancer immunotherapeutic, DV281, is in Phase 1 development.
keywords:N/A
$1B
Total Funding
423
Number of Employees
$91.8M
Revenue (est)
16%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Dynavax Technologies News
Dynavax Technologies (DVAX) Scheduled to Post Quarterly Earnings on Thursday. Posted by admin on Apr 28th, 2022. Share on Twitter Share on Facebook Share on...
Dynavax Technologies Co. (NASDAQ:DVAX) Receives Consensus Rating of Buy from Analysts. Posted by admin on Apr 22nd, 2022.
EMERYVILLE, Calif., April 21, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical...
EMERYVILLE, Calif., Nov. 4, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the third quarter ended September 30, 2021 and provided a business update. ...
EMERYVILLE, Calif., Oct. 18, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Valneva SE reported positive topline results from the Phase 3 pivotal trial of VLA2001, their in ...
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $142.8M | 423 | 9% | N/A |
#2 | $15M | 423 | 6% | N/A |
#3 | $142.8M | 423 | 5% | N/A |
#4 | $126.4M | 423 | 6% | N/A |
#5 | $122.2M | 424 | 24% | $25M |